ABCL vs NTRA
AbCellera Biologics Inc. vs Natera, Inc. — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
67
Buy
VS
| Metric | ABCL | NTRA |
|---|
| AI Score |
67
|
67
|
| Price |
$11.38
|
$309.83
|
| P/E Ratio |
-21.07×
|
-227.89×
|
| ROE |
-15.1%
|
-12.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
65.3%
|
| Debt / Equity |
0.15×
|
0.13×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
93.5
|
65.5
|
| Beta |
1.191
|
1.514
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABCL versus NTRA.
The committee scores are tied.
ABCL and NTRA both score 67/100.
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 93 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
NTRA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 37.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 18.5x prices in significant intangible value — Value
- ROE of only -11.7% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 34.9% signals elevated volatility — Risk